BG
RCKT icon

Bellevue Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Bellevue Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,300
Closed -$172K – 172
2024
Q3 		$172K Sell
9,300
-10,400
-53% -$213K ﹤0.01% 151
2024
Q2 		$424K Hold
19,700
– – 0.01% 132
2024
Q1 		$531K Sell
19,700
-1,300
-6% -$36.9K 0.01% 129
2023
Q4 		$629K Buy
+21,000
New +$463K 0.01% 130
2023
Q3 		– Sell
-55,600
Closed -$1.1M – 162
2023
Q2 		$1.1M Buy
55,600
+19,000
+52% +$384K 0.02% 128
2023
Q1 		$627K Hold
36,600
– – 0.01% 138
2022
Q4 		$716K Buy
+36,600
New +$674K 0.01% 145

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.6B AUM 48.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return